SELLAS is drawing attention as its Phase 3 REGAL AML trial approaches the 80th death event that will trigger final efficacy analysis, with traders focused on the prospect of a major binary catalyst. Bulls point to the prolonged survival timeline and supportive comments from pharmaceutical-industry professionals, while bears debate trial design, dosing changes, censoring, and whether the delay signals control-arm strength or statistical risk.

A sharp rally in the thinly traded, low-market-cap token has fueled speculation of a potential short squeeze, with traders pointing to outsized futures positioning, rising volume and renewed momentum. Bullish participants cite Zoras creator- and attention-market ecosystem, while skeptics view the move as a temporary pump-and-dump and note its broader sensitivity to Bitcoin and altcoin sentiment.

Cathie Woods ARK Invest buying and expanding its SpaceX exposure has become the dominant focus, with traders debating whether the concentrated bet strengthens ARKKs innovation strategy or reflects poor timing and excessive risk. The discussion is broadly split between bullish expectations for space, AI and other high-beta holdings and criticism of ARKKs volatility, rebalancing decisions and long-term underperformance.

Modernas reported positive Phase 3 cancer-vaccine result has made ARCT a sympathy trade, drawing attention to Arcturuss self-amplifying mRNA platform and related oncology potential. Bulls are also highlighting upcoming CF and OTC-deficiency milestones and short interest, while skeptics point to mixed ARCT-032 data and caution that the rally may be technically overbought.

Upcoming earnings are the main catalyst, with traders focused on whether Oracles AI-cloud demand, data-center backlog and new partnerships can offset concerns about heavy capital spending and debt. Bullish participants anticipate a pre-earnings rally and short covering, while skepticsincluding traders citing Michael Burrys short thesisexpect pressure from financing, margin and OpenAI-related risks.

Michael Burrys reported increase in his Lululemon position has reinforced a contrarian, value-focused trade ahead of upcoming earnings. Traders remain divided, with bulls citing the stocks depressed valuation, potential tariff refunds and incoming CEO, while bears point to weak consumer demand, competition and broader apparel-sector pressure; the tariff benefit remains speculative.

Progress on the proposed European Lithium merger including an amended floating share-exchange ratio, potential cancellation of existing CRML shares, court proceedings, and expected cash inflowhas driven the dominant discussion. Bullish traders view the deal as reducing dilution and strengthening CRMLs rare-earths and lithium platform, while skeptics remain focused on execution delays, future dilution, and the companys pre-revenue status, with short-squeeze speculation amplifying volatility.

Apples CEO transition from Tim Cook to John Ternus and the upcoming September 9 iPhone launchexpected to feature a foldable model and expanded AI capabilitiesare driving attention. Traders are split between expecting a pre-event rally on the new product cycle and warning that the expensive foldable, Apples AI lag, valuation, and a potential sell-the-news reaction could limit upside.

Salesforces strong quarterly results, raised outlook, and expanded Anthropic partnership through Claudeforce have fueled a sharp rally, reinforcing the view that AI can augmentand monetizeenterprise software rather than replace it. Traders are broadly bullish and citing short covering and a broader software rotation, though some warn the move is overextended and expect profit-taking or a pullback.

Amazons planned acquisition of Globalstar is the dominant catalyst, with traders focused on the merger spread, cash-versus-Amazon-share consideration, and the timeline and conditions for closing. The community is split between viewing the deal as a relatively defined outcome and speculating that SpaceX or another bidder could make a superior offer, though no competing bid is confirmed.